ASX:SPL - HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model

Starpharma

Company

About Starpharma Leadership Our Brands Our Capabilities Research Publications ESG

DEP® Platform

Dendrimer Technology DEP® Drug Delivery Platform DEP® Solutions

Partnerships

Partnering with Starpharma Star Navigator

Investors

Why Invest ASX Announcements News & Updates Investor Presentations Video Library Financial Reports Annual General Meeting 2025 Market Data Stock Listing Shareholder Services Corporate Governance

People & Culture

Our People & Culture Careers

HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model

Your question will be sent privately to Starpharma. The company may choose to make this question public.

Start the conversation

Ask Starpharma a question about this announcement.

Share your feedback

Discover